Always Remember - Buy The Dip

Sentiment Analysis For AKAO

The news is currently generally neutral for AKAO.

Based on TextBlob analysis of Yahoo! Finance news summaries for AKAO on 2015-09-08.

Yahoo! Finance News for AKAO

Can The Uptrend Continue for Achaogen (AKAO)? - Tale of the Tape
Investors certainly have to be happy with Achaogen, Inc. ( AKAO ) and its short term performance. After all, the stock has jumped by 9.4% in the past 4 weeks, and it is also above its 20 Day Simple

Achaogen (AKAO) Looks Good: Stock Moves 8.9% Higher - Tale of the Tape
Achaogen, Inc. ( AKAO ) was a big mover last session, as the company saw its shares rise almost 9% on the day. The move came on solid volume too with far more shares changing hands than in a

Why Earnings Season Could Be Great for Achaogen, Inc. (AKAO) - Tale of the Tape
Investors are always looking for stocks that are poised to beat at earnings season and Achaogen, Inc. ( AKAO ) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite

Achaogen (AKAO) is in Overbought Territory: What's Next? - Tale of the Tape
Achaogen, Inc. ( AKAO ) has moved higher as of late, but there could definitely be trouble on the horizon for this company. That is because AKAO is now in overbought territory with an RSI value of 76.28.What is

Biotechs post better returns this week before an IPO tech wave
Last week's two biotech IPOs Aquinox Pharmaceuticals ( AQXP ) and Recro Pharma ( REPH ) posted an average return of only 6% on their first day of trading on Friday. While Recro

Achaogen prices upsized IPO at $12, the low end of the range
Achaogen, which is developing antibiotic treatments for multi drug resistant infections, raised $72 million by offering 6.0 million shares at $12, at the low end of the $12 to $14 range. Insiders that previously indicated an intent

6 US IPOs planned for the week of Mar 10
The following IPOs are expected to price this week Achaogen ( AKAO ), which is developing antibiotic treatments of multi drug resistant infections, plans to raise $65 million by offering 5.0 million shares at a price

Antibacterial biotech Achaogen sets terms for $65 million IPO
Achaogen, which is developing antibacterials for the treatment of multi drug resistant infections, announced terms for its IPO on Tuesday. The South San Francisco, CA based company plans to raise $65 million by offering 5 million shares